Listing 14.04 Systemic Sclerosis and Scleroderma in 2026: The Four Paths To Approval, the Two Constitutional Symptoms Rule, and How Raynaud's Gangrene and Finger Contractures Trigger Automatic Disability

By Anthony Albert, Benefits Research Director, Disability Exchange · Published July 13, 2026

Systemic sclerosis, more commonly called scleroderma, is one of the immune system diseases where SSA built a listing with multiple paths to approval. Not one criterion. Four. If any single one applies to your case, you meet the listing. That flexibility is unusual for the Blue Book, and it exists because scleroderma presents so differently across patients. Some get severe Raynaud's with gangrene. Others get diffuse skin thickening and joint contractures. Others get pulmonary and cardiac involvement without the classic hand findings. Others get slow progressive fatigue with organ damage but no gangrene, no contractures, no acute crisis.

This article walks through all four paths in Listing 14.04, what each requires, how DDS and ALJs interpret the terms, and two 2026 case walkthroughs showing what a clean scleroderma approval looks like. If you have scleroderma and you're wondering whether you qualify for SSDI, one of the four paths probably applies to you. Getting the right one documented is the difference between a fast listing approval and a two-year fight.

What SSA means by systemic sclerosis

SSA's Section 14.00D3 defines systemic sclerosis (scleroderma) as a spectrum of disease where thickening of the skin is the clinical hallmark. That spectrum includes three main forms:

1. Diffuse cutaneous systemic sclerosis (diffuse scleroderma): widespread skin thickening plus major organ involvement (GI tract, lungs, heart, kidneys, muscle).
2. Limited cutaneous systemic sclerosis: also called CREST syndrome (Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia). Progresses more slowly. Can eventually become the generalized process.
3. Localized scleroderma: linear scleroderma and morphea, more common in children but can persist into adulthood. Evaluated under musculoskeletal (1.00) or other body-system listings depending on presentation.

Listing 14.04 covers systemic sclerosis (the first two forms above). Localized scleroderma is evaluated under other listings. That distinction matters at the DDS level: if you have localized scleroderma with facial disfigurement, your case goes through Section 2.00 (special senses) or 12.00 (mental disorders), not 14.04.

Path A: Two or more organ systems involved with constitutional symptoms

Path A is the broadest and most commonly used route to 14.04 approval. It requires:

• Involvement of two or more organs or body systems, with at least one of them at a moderate level of severity, AND
• At least two of the constitutional symptoms or signs: severe fatigue, fever, malaise, or involuntary weight loss.

The organs and body systems that count include:

• Skin (sclerodactyly, diffuse thickening, digital ulcers, calcinosis)
• Gastrointestinal tract (esophageal dysmotility with reflux, gastric involvement, small bowel dysmotility, pseudo-obstruction, malabsorption)
• Lungs (interstitial lung disease, pulmonary hypertension)
• Heart (myocardial involvement, pericarditis, arrhythmias)
• Kidneys (scleroderma renal crisis, chronic kidney disease)
• Muscles (myositis, muscle weakness)
• Joints (arthralgia, contractures, tendinopathy)
• Peripheral vascular (severe Raynaud's, digital ischemia)

"Moderate level of severity" is not defined with numeric thresholds in the listing itself. In practice, DDS medical consultants interpret it as involvement that measurably impairs function. Examples: interstitial lung disease with FVC 60-75% predicted, mild-to-moderate pulmonary hypertension (mPAP 25-40 mm Hg), esophageal dysmotility with reflux-related weight loss, or Raynaud's with recurrent digital ischemia.

Constitutional symptoms need to be documented in medical records. Fatigue must be described as severe. Weight loss must be involuntary and measurable (typically 10 or more pounds over 6-12 months). Fever must be documented on multiple occasions. Malaise must be described in provider notes.

Path B: Contractures, atrophy, or fixed deformities with mobility loss

Path B focuses on physical function loss from scleroderma's skin and musculoskeletal effects. It has four sub-paths:

B1: Toe contractures or fixed foot deformity

Toe contractures or fixed deformity in one or both feet PLUS documented medical need for either:

• Walker, bilateral canes, or bilateral crutches, or a wheeled mobility device requiring both hands, OR
• Inability to use one upper extremity for work-related fine and gross movements AND documented need for a one-handed assistive device that requires the other upper extremity.

B2: Finger contractures or fixed hand deformity in both hands

Finger contractures or fixed deformity in both hands AND documented inability to use both upper extremities to independently initiate, sustain, and complete work-related activities involving fine and gross movements. This is the classic sclerodactyly with severe hand function loss path.

B3: Atrophy with irreversible damage in lower extremities

Atrophy with irreversible damage in one or both lower extremities PLUS the same mobility device requirements as B1.

B4: Atrophy in both upper extremities

Atrophy with irreversible damage in both upper extremities AND documented inability to use both upper extremities for work-related fine and gross movements.

Path B is objective. Physical exam findings and imaging (MRI showing muscle atrophy, X-rays showing joint deformity, occupational therapy assessments documenting range of motion loss) drive the decision. A rheumatologist or occupational therapist assessment of hand function is central.

Path C: Raynaud's phenomenon with gangrene or ischemic ulceration

Path C is the acute vascular manifestation path. It requires Raynaud's phenomenon characterized by:

1. Gangrene involving at least two extremities, OR
2. Ischemia with ulcerations of toes or fingers, PLUS documented medical need for a walker/bilateral canes/bilateral crutches, wheeled device requiring both hands, or inability to use one or both upper extremities for work-related activities.

This path applies when Raynaud's has progressed to actual tissue damage. Not just pain or color change on cold exposure. Gangrene or ischemic ulcerations that don't heal are the trigger. Digital amputation for gangrene supports Path C. Chronic non-healing digital ulcers on multiple fingers supports Path C.

Documentation needed: dermatology or rheumatology notes showing gangrene or ulcerations, wound care records, photographs when possible, and functional assessment showing inability to use hands.

Path D: Repeated manifestations with marked functional limitation

Path D is the flexible catch-all. It requires:

• Repeated manifestations of scleroderma, AND
• At least two constitutional symptoms or signs (severe fatigue, fever, malaise, involuntary weight loss), AND
• One of the following at a MARKED level:
  1. Limitation of activities of daily living (ADLs)
  2. Limitation in maintaining social functioning
  3. Limitation in completing tasks in a timely manner due to deficiencies in concentration, persistence, or pace

"Marked" is a specific term in SSA disability law. It's less than "extreme" but more than "moderate." It's a serious limitation that interferes with the ability to function independently, appropriately, effectively, and on a sustained basis. Not something you overcome with effort. A limitation you cannot work around most of the time.

Documentation for Path D: Multiple flares or manifestations of scleroderma over time (annual disease progression, hospital visits, medication changes for disease flares), constitutional symptoms in provider notes, plus a specific functional assessment describing marked limitation in ADLs, social functioning, or concentration/persistence/pace.

For the "marked concentration/persistence/pace" prong, brain fog from disease activity, fatigue interfering with focus, and medication side effects (steroids, immunosuppressants, methotrexate) can all contribute. Documentation from primary care and rheumatology should describe these effects specifically.

Worked case A: Patricia, 51, Charleston SC, diffuse scleroderma with lung and GI involvement

Worked case B: Jamal, 47, Detroit MI, CREST with Raynaud's gangrene

What's under moderate versus marked severity

The most common denial in scleroderma cases is DDS finding the organ involvement isn't at "moderate severity" for Path A or the functional limitation isn't "marked" for Path D. Here's how to frame the medical evidence:

• ILD is moderate when FVC is between 60% and 75% predicted, or when there is evidence of progressive disease on serial imaging.
• Pulmonary hypertension is moderate when mPAP is 25-40 mm Hg by right heart catheterization, or when echo shows RVSP over 40 mm Hg with functional impact.
• GI involvement is moderate when there is documented dysphagia, dysmotility with symptomatic reflux, malabsorption, or measurable weight loss over 6-12 months.
• Kidney involvement is moderate when there is evidence of scleroderma renal crisis or CKD stage 3 or higher.
• Marked ADL limitation means you can't perform essential daily tasks independently and consistently. Not "sometimes struggles." Consistently can't or requires help.
• Marked concentration/persistence/pace limitation means you cannot sustain focused work for meaningful periods due to fatigue, brain fog, pain, or medication side effects. Documented breaks needed. Task completion delays.

Common documentation gaps that cause denials

1. Missing constitutional symptoms. Providers know your fatigue and weight loss but don't always chart them. Ask your rheumatologist to document severe fatigue, involuntary weight loss (with specific numbers), fever, or malaise on every visit.
2. PFT results without functional context. DDS sees FVC numbers but not always the functional impact. Ask your pulmonologist to describe your exertional tolerance and how ILD affects daily activities.
3. Occupational therapy assessment missing. For Path B and Path C cases where hand function is central, an OT assessment quantifying inability to perform work-related fine and gross motor tasks is critical. Get one before filing.
4. Fatigue described but not connected to function. "Patient reports fatigue" doesn't help. "Patient reports severe fatigue requiring 3-4 hour daily rest periods, unable to complete household tasks without breaks" does help.
5. No timeline of manifestations for Path D. Path D requires "repeated manifestations." That means multiple flares, hospitalizations, or disease-related events over time. Your rheumatology chart should tell that story.

Treatment options and disease progression

Current 2026 scleroderma treatment options include:

• Immunosuppression: mycophenolate mofetil (first-line for skin and ILD), cyclophosphamide (for severe ILD), methotrexate (for skin), rituximab (increasingly used).
• Autologous stem cell transplant: for aggressive early diffuse scleroderma in patients who can tolerate the procedure. Can slow or stabilize disease progression.
• Nintedanib and pirfenidone: antifibrotic agents FDA-approved for scleroderma-associated ILD (SSc-ILD).
• Vasodilators for Raynaud's: calcium channel blockers (nifedipine, amlodipine), sildenafil, iloprost, bosentan.
• Renal crisis treatment: ACE inhibitors (captopril, lisinopril) are the standard and can be lifesaving.
• PPIs and prokinetics for GI: omeprazole, esomeprazole, plus prokinetics like metoclopramide or prucalopride.

SSA does not require you to fail treatment before qualifying under 14.04. If you meet the listing criteria, you meet them regardless of what medications you're on. But treatment records provide the documentation trail that supports disease severity and progression.

Continuing disability review considerations

Scleroderma is chronic. Some patients stabilize on treatment. Others progress despite treatment. If you're approved under 14.04, CDRs typically occur every 3-7 years depending on the specific manifestations. If your disease has stabilized on treatment (skin softens with mycophenolate, ILD stable on nintedanib), CDR will look at whether you still meet the listing criteria.

For most patients on Path A with multi-organ involvement, ongoing rheumatology documentation of the same organ systems continues to support the listing. For Path B and C cases based on contractures, atrophy, or Raynaud's gangrene, the underlying tissue changes are typically irreversible and continue to meet the listing.

State pages and related listings

• South Carolina SSDI resources
• Michigan SSDI resources
• Ohio SSDI resources
• Pennsylvania SSDI resources

• Listing 5.07 Intestinal Failure Short Bowel Syndrome SSDI 2026
• Listing 3.09 Chronic Pulmonary Hypertension SSDI 2026
• Listing 5.08 Weight Loss Digestive Disorder SSDI 2026

Frequently asked questions